‘First and Only’ Sublingual Treatment for Off Episodes in Parkinson’s Disease Gets Approval from FDA

Sunovion Pharmaceuticals, Inc. recently announced, the U.S. Food and Drug Administration has approved the KYNMOBITM sublingual film for the severe, sporadic treatment of off episodes in individuals who have Parkinson's disease.

Off episodes, as MedicalResearch.com describes, are the recurrence of the symptoms of P.D. otherwise managed with "levodopa or carbidopa." 

More so, "off episodes" are characterized, partly, by stiffness, tremor, slowed movement, or other indications. These disruptive episodes can take place in the morning and throughout the day.

Essentially, KYNMOBI dissolves under a P.D. patient's tongue to help him improve his "Off symptoms as needed."

ALSO READ: 5 Benefits of Fennel Seeds

Advancement in Treatment Options Among P.D. Patients

The approval of KYNMOBI recently advances treatment for individuals suffering from P.D. and experiencing off episodes and the linked disruption of daily activities. This was according to Sunovion CEO and President Anthony Loebel, M.D.

Loebel also said they are pleased to offer the P.D. community a novel cure option, which they believe, would provide a convenient way for individuals with Parkinson's disease to improve movements and better manage their "motor systems.

Parkinson's disease is a prolonged neurodegenerative illness in which there is a loss in "dopamine-producing cells. It is approximated that more than a million Americans will live with the disease by 2030.

Within up to six weeks after a patient gets diagnosed, no matter how severe or mild P.D. is, up to 60 percent of those with P.D. suffer from Off episodes.

DON'T MISS THIS: Blood, Salivary, and Fecal Home Test Kits: Yay or Nay?

Additional to Medication

A couple of years after an individual diagnosed with P.D., he may notice some problems with his day-to-day activities like getting out of bed upon waking up or finding it hard to get out of a chair. 

According to Neurology Professor, Stewart Factor, D.O., who is also the Movement Disorders Program Director, and Chair of Neurology at Emory University School of Medicine, a P.D. patient may also feel frozen while walking, as the impact of his maintenance drug declines. 

Factor also said, the approval of this new rapid treatment for P.D. "affords health care providers with a need" choice that can be an addition to the medication regimen of their patients to address OFF episodes as their P.D. progresses adequately.

Sunovion expects the availability of KYNMOBITM sublingual film in various pharmacies in the U.S. in September this year.

What You Need to Know about KYNMOBITM

KYNMOBI sublingual film, as explained by experts in medicine, is a fresh and innovative preparation of "apomorphine, a dopamine agonist," that's the first and lone sublingual treatment for rapid-acting, on-demand cure of "off episodes" linked with P.D. 

 This new medicine may be taken five times a maximum each day. Essentially, KYNMOBI is a prescription drug used to cure short-term sporadic off episodes in individuals who have Parkinson's disease.

It is important to know, too, that it is unknown that KYNMOBI is safe to use and effective in children. Also, one shouldn't take the drug with a nausea treatment known as 5HT3 that includes granisetron, ondansetron, palonosetron, alosetron, and dolasetron.

IN CASE YOU MISSED THIS: Vitamin D as a COVID-19 Breakthrough and How It Can Alleviate the Impact on BAME People